Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

Hadassah Medical Center

Status: Unknown

Conditions: H1N1 Influenza

Study type: Observational

Funder types: Other

Identifiers

NCT01008683

engelhard-HMO-CTIL

Details and patient eligibility

About

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

In these patients the investigators will measure the specific antibody production.

Full description

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. Two doses will be given, in 3-week interval.

In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.

Enrollment: 300 estimated patients

Sex: All

Ages: Under 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

Exclusion criteria

• Patients with unstable grafts.

Trial design

300 participants in 1 patient group

Stem cell and and heart transplant patients

Description:

Stem cell and and heart transplant patients